Invalidity dossier
US 10973827
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Current assignee: Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG
Added 9/16/2026, 6:46:41 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US10973827B2
Title: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Patent number: US10973827B2 | Application: US16/676,643 | Publication (A1): US20200069693A1
Inventor(s): Thomas Friedl; Michael Braun; Kenji Egusa; Hikaru Fujita; Megumi Maruyama; Takaaki Nishioka
Assignee: Boehringer Ingelheim International GmbH (original and current, per the listing, which states assignees may be inaccurate)
Key dates: Priority date (assumed): 2008-04-03; Filing date: 2019-11-07; Publication date: 2021-04-13; Anticipated expiration: 2029-04-02. Status listed as Active.
Purpose & scope (plain language): The patent concerns tablet formulations that combine a DPP-IV inhibitor (a class of antidiabetic compound) with a further antidiabetic agent. The text lists chemical structures for numerous DPP-IV inhibitor compounds and uses keywords such as "methyl," "tablet," "DPP," "metformin," and "film," indicating tablets—including film-coated tablets—containing such combinations, plus their use and a process for making them.
Classifications (excerpt): A61K45/06 (mixtures of active ingredients without chemical characterisation), A61K9/20 (pills, tablets, discs, rods), A61K9/28 (coated pills or tablets, e.g. film or compression coating), A61K31/155 (amidines/guanidine, e.g. metformin), and various heterocyclic-compound classes (A61K31/40, /495, /505, /519, /52, /522).
Source: https://patents.google.com/patent/[US10973827](/patent/US10973827)/en
What the excerpt does not establish: It provides no claim text, so the exact metes of the claimed invention are not shown. It does not specify which DPP-IV inhibitor or which "further antidiabetic agent" is claimed, nor dosages, formulation details, or a detailed process. The excerpt contains only chemical structures and classification data, not examples, tables, or efficacy results. Priority date and assignee accuracy are expressly labeled assumptions/disclaimers in the source.
Generated 10/1/2026, 10:03:29 PM
Cases on file (1)
Group view →Specific litigation cases in our database that name US patent 10973827. The free-form analysis below may also discuss cases beyond this list.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
Current assignee: Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.
Keep exploring
More patents asserted by Boehringer Ingelheim Pharmaceuticals Inc.
- US 9415016I'll search for authoritative information on US 9415016, including its claims and any 2026 CAFC docket activity. Let me look for the claim text of US 9415016 and any Federal Circuit activity. Let me try to retrieve the actual claim set…
- US 10022379Patent Overview — US 10022379 B2 Title: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation. Patent number / application: US 10022379 B2…
- US 11911388Patent Overview: US11911388B2 Title: Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug Assignee: Boehringer Ingelheim International GmbH Key dates: Priority…
- US 9155705Patent Overview: US 9,155,705 B2 Title: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation. Assignee: Boehringer Ingelheim International GmbH…
This patent in court (1)
1 tracked lawsuit name US 10973827.